The importance of PARP in cellular physiology has led to the use of PARP inhibitors in the treatment of certain cancers, including ovarian, breast, and prostate malignancies [26–29], as well as pre-clinical and clinical trials for neurodegenerative diseases [30–32], including retinal diseases [30–32]. This evidence concerns the gene PARP1 and cancer.